Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (51-60 of 499) with videos related to

Pageof 50
Sort By:
Oncology (Williston Park, N.Y.)|December 25, 2007
Clinical presentation and pathophysiology of EGFRI dermatologic toxicitiesEdith P Mitchell, Roman Perez-Soler, Eric Van Cutsem, et al.
ESMO Open|June 25, 2019
Maximising clinical benefit with adequate patient management beyond the second line in mCRCGuillem Argiles, Dirk Arnold, Gerald Prager, et al.
Journal of Surgical Oncology|December 18, 2010
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodiesRavit Geva, Hans Prenen, Baki Topal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Skin toxicities of targeted therapiesSiegfried Segaert, Gabriela Chiritescu, Liesbeth Lemmens, et al.
Oncotargets and Therapy|February 5, 2013
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancerRavit Geva, Loredana Vecchione, Sabine Tejpar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabSabine Tejpar, Ilhan Celik, Michael Schlichting, et al.
Cancers|April 25, 2020
An Explorative Analysis of <i>ABCG2/TOP-1</i> mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 TrialJan Stenvang, Eva Budinská, Eric van Cutsem, et al.
Clinical Colorectal Cancer|November 26, 2015
Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard TreatmentEric Van Cutsem, Takayuki Yoshino, Julia Hocke, et al.
Clinical Colorectal Cancer|October 6, 2010
The timing of chemotherapy and surgery for the treatment of colorectal liver metastasesBernard Nordlinger, Jean-Nicolas Vauthey, Graeme Poston, et al.
Annals of Surgical Oncology|September 16, 2010
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiationAlbert M Wolthuis, Freddy Penninckx, Karin Haustermans, et al.
Pageof 50

Showing results (51-60 of 499) with videos related to

Sort By:
Pageof 50
Oncology (Williston Park, N.Y.)|December 25, 2007
Clinical presentation and pathophysiology of EGFRI dermatologic toxicitiesEdith P Mitchell, Roman Perez-Soler, Eric Van Cutsem, et al.
ESMO Open|June 25, 2019
Maximising clinical benefit with adequate patient management beyond the second line in mCRCGuillem Argiles, Dirk Arnold, Gerald Prager, et al.
Journal of Surgical Oncology|December 18, 2010
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodiesRavit Geva, Hans Prenen, Baki Topal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Skin toxicities of targeted therapiesSiegfried Segaert, Gabriela Chiritescu, Liesbeth Lemmens, et al.
Oncotargets and Therapy|February 5, 2013
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancerRavit Geva, Loredana Vecchione, Sabine Tejpar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabSabine Tejpar, Ilhan Celik, Michael Schlichting, et al.
Cancers|April 25, 2020
An Explorative Analysis of <i>ABCG2/TOP-1</i> mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 TrialJan Stenvang, Eva Budinská, Eric van Cutsem, et al.
Clinical Colorectal Cancer|November 26, 2015
Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard TreatmentEric Van Cutsem, Takayuki Yoshino, Julia Hocke, et al.
Clinical Colorectal Cancer|October 6, 2010
The timing of chemotherapy and surgery for the treatment of colorectal liver metastasesBernard Nordlinger, Jean-Nicolas Vauthey, Graeme Poston, et al.
Annals of Surgical Oncology|September 16, 2010
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiationAlbert M Wolthuis, Freddy Penninckx, Karin Haustermans, et al.
Pageof 50